RBC Capital Defends XenoPort (XNPT); Analyst Notes M&A Potential
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- S&P 500, Dow on course for slim gains at open as Iran tensions clash with AI optimism
- Oil retreats from one-month high as traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
XenoPort Announces Positive Phase 2 Study Results for XP23829 as a Potential Treatment for Patients with Psoriasis
September 15, 2015 6:30 AM EDTEfficacy observed with both 800 mg once-daily and 400 mg twice-daily XP23829 dosing XP23829 safe and generally well-tolerated with low incidence of flushing similar to placebo Low incidence/severity of lymphopenia seen with XP23829 First clinical demonstration of efficacy of a MMF prodrug other than DMF
SANTA CLARA, Calif.--(BUSINESS WIRE)-- XenoPort, Inc. (Nasdaq: XNPT) announced today positive preliminary top-line results from its Phase 2 clinical trial of XP23829 as a potential... More
